

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

4			<u>\$</u>			
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/746,662	12/22/2000	Lechoslaw Turski	102286-123	1433		
	90 07/29/2002					
HALE AND D		EXAMINER				
60 STATE STR BOSTON, MA		LI, RUIXIANG				
3			ART UNIT	PAPER NUMBER		
!				1646		
,			DATE MAILED: 07/29/2002 10			

Please find below and/or attached an Office communication concerning this application or proceeding.

. -			Applic	ation No.	A	pplicant(s)			
-	•		09/74			JRSKI ET AL.			
•	Offic	Action Summary	Exami	· · · · · · · · · · · · · · · · · · ·		rt Unit			
		•	Ruixia			846			
	The MAI	LING DATE of this commun					dress		
	for Reply								
THE - Ex afi - If i - If i - Fa - Ar	E MAILING I densions of time ter SIX (6) MONT the period for rep NO period for rep sillure to reply with ay reply received	O STATUTORY PERIOD F DATE OF THIS COMMUN may be available under the provisions HS from the mailing date of this comr y specified above is less than thirty (3 by is specified above, the maximum st in the set or extended period for reply by the Office later than three months adjustment. See 37 CFR 1.704(b).	ICATION. s of 37 CFR 1.136(a). In nonunication. s0) days, a reply within the ratutory period will apply are y will, by statute, cause the	o event, however, n statutory minimum nd will expire SIX (6 application to beco	nay a reply be timely of thirty (30) days will honths from the time ABANDONED (3	filed be considered timely mailing date of this co U.S.C. § 133).	y. ommunication.		
Jiaius 1)∑	7 Respons	sive to communication(s) fi	led on <i>29 May 200</i>	12					
2a)[_	on is FINAL .	2b)⊠ This action						
3)[_	s application is in conditio	,		ıl matters, prose	ecution as to th	e merits is		
•	closed ir ition of Cla	accordance with the prac	tice under <i>Ex parte</i>	e Quayle, 193	5 C.D. 11, 453	O.G. 213.			
4)[>	4)⊠ Claim(s) <u>1-14 and 18-20</u> is/are pending in the application.								
	4a) Of the above claim(s) 3,7,11 and 13 is/are withdrawn from consideration.								
5)[) Claim(s) is/are allowed.								
6)[∑	6)⊠ Claim(s) <u>1,2,4-6,8-10 and 12</u> is/are rejected.								
7)[∑	Claim(s)	<u>14 and 18-20</u> is/are object	ed to.						
8)[are subject to restri	ction and/or electio	n requiremen	t.				
	ation Paper								
9) The specification is objected to by the Examiner.									
10)⊵		ng(s) filed on <u>22 Decembe</u>					r.		
44)		t may not request that any ob							
11)∟		sed drawing correction file)∐ disapprove	a by the Examin	er.		
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.									
,	_	•	by the Examiner.						
_		J.S.C. §§ 119 and 120			0 0 0 440(a) (a	d) == (f)			
	_	dgment is made of a claim	tor foreign priority	under 35 U.S	5.C. § 119(a)-(c	a) or (1).			
ć		Some * c) None of:			•				
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.									
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachm			-						
2) 🔲 No	tice of Draftspe	ces Cited (PTO-892) erson's Patent Drawing Review (I sure Statement(s) (PTO-1449) F			rview Summary (P ce of Informal Pate er:				

Application/Control Number: 09/746,662

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

1. Applicants' election with traverse of Group I (Claims 1, 2, 4-6, 8-10, 12, 14, and 18-20) in Paper No. 9 filed on 05/29/2002 is acknowledged. The traversal is on the ground that the subject matter of Groups I and II is so closely related that a search of one group inevitably will reveal art relevant to the other and thus simultaneous search and examination would not be unduly burdensome. This is not found persuasive because while both AMPA receptors and kainite receptors belong to ionontropic glutamate receptors, the two types of receptors do have distinct entity and require separate search. Even if the search on one receptor may reveal the art relevant to the other receptor, examination of the two receptors requires separate consideration. Consequently search and examination constitute an unduly burden on the office.

Applicants further elected amino- or desamino-2,3-benzodiazepine for prosecution of Claims 8 and 9, and elected an interferon for prosecution of Claims 14 and 19.

The requirement is still deemed proper and is therefore made FINAL.

2. Applicants' amendment filed in Paper No. 5 on 12/22/200 is acknowledged. The title of the application has been changed to read as "Treatment of demyelinating disorders". Claims 15-17 have been canceled, Claims 1-14 have been amended, and Claims 18-20 have been added. Claims 1-14 and 18-20 are pending, Claims 1, 2, 4-6, 8-10, 12, 14, and 18-20 are under consideration. All other claims are withdrawn

from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Priority

3. Acknowledgment is made of applicant's claim for foreign priority based on application PCT GB99 02112, filed on July 2, 1999 under 35 U.S.C. 119(a)-(d), and for PCT international applications (PCT GB 98/14380.3, filed on 07/02/1998; PCT GB 98/24393.4, filed on 11/06/1998) designating the U.S. for benefit under 35 U.S.C. 120.

Drawings

4. The drawings, Figs. 1-8, are accepted by the Examiner.

Information Disclosure Statement

5. The Information Disclosure Statement filed on May 7, 2001 in paper No. 6 is acknowledged. However, It is incomplete because form PTO-1449 (including 15 documents) and a copy of the International Search report have not been received by the Office. Applicants are required to submit a PTO-1449 form and to provide the references listed in the form.

Claim Rejections—35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1646

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

7. Claims 1, 2, 4-6, 8, and 9 are rejected under 35 U.S.C. 102(e) as being anticipated by Csuzdi et al. (U.S. Patent No. 6,323,187 B1, November 27, 2001; filed on July 31, 1998).

Csuzdi et al. teach condensed 2,3-benzodiazepine derivatives, including amino- or desamino-2,3-benzodiazepine, a composition comprising the compounds, and the use as AMPA receptor inhibitors (See, Abstract and Claims). Thus, the reference taught by Csuzdi et al. meets the limitations of Claims 1, 2, 4-6, 8, and 9.

8. Claims 1, 2, 4, 5, 10, and 12 are rejected under 35 U.S.C. 102(b) as being anticipated by Keller et al. (DE 4239816 A1, June 1, 1994).

Keller et al. teach an AMPA receptor channel blocker, Joro spider toxin, and a composition comprising the molecule (See, e.g., abstract). Thus, the reference taught by Keller et al. meets the limitations of Claims 1, 2, 4, 5, 10, and 12.

Claim Objection—Minor Informalities

9. Claims 1, 2, 4, 5, 8, 14, and 18-20 are objected to because of the following

informalities: (a) Claims 1, 18, and 19 recite the abbreviation "AMPA" which should

be spelled out in all independent claims for the interest of clarity; (b) there are two "."

at the end of the Claim 2; (c) there is a typographic error in "benzodiazepine" in claim

8 (line 9); "with combined with" in claim 19 (line 4) also appears to be a typographic

error. (d) Claims 1, 4, 5, 14, and 18-20 recite an unelected subject matter (an inhibitor

of the interaction of glutamate with the kainite receptor).

Appropriate correction is required.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Ruixiang Li whose telephone number is (703) 306-0282.

The examiner can normally be reached on Monday-Friday, 8:30 am-5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Yvonne Eyler, can be reached on (703) 308-6564. The fax phone number

for this Group is (703) 305-3014 or (703) 308-4242.

Communications via Internet e-mail regarding this application, other than those

under 35 U.S.C. 132 or which otherwise require a signature, may be used by the

applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO

employees do not engage in Internet communications where there exists a possibility

Application/Control Number: 09/746,662 Page 6

Art Unit: 1646

that sensitive information could be identified or exchanged unless the record includes a

properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122.

This is more clearly set forth in the Interim Internet Usage Policy published in the Official

Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the Group receptionist whose telephone number is

(703) 308-0196.

Ruixiang Li Examiner

July 21, 2002

YVONNE EYLER, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600